Molecular Mechanisms for Carbohydrate Presentation to CD4+ T cells by MHCII Pathway
Molecular Mechanisms for Carbohydrate Presentation to CD4+ T cells by MHCII Pathway
批准号:
9919487
负责人:
Fikri Y Avci
金额:
$37.5万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-06-06 至 2022-09-16
关键词:
APC VaccineAdaptive Immune SystemAdoptive TransferAntibodiesAntigen-Presenting CellsAntigensB-LymphocytesBacteriaBacterial InfectionsBacterial ModelBacterial PolysaccharidesBindingBiologicalBiological AssayCD4 Positive T LymphocytesCarbohydratesCarrier ProteinsCell surfaceCellsCellular StructuresChemicalsChemistryClone CellsCommunicable DiseasesCompetitive BindingComplexComprehensionConjugate VaccinesDataDisaccharidesEpitopesFutureGenerationsGlycoconjugatesHealthHealth BenefitHelper-Inducer T-LymphocyteHistocompatibility Antigens Class IIHumanImmuneImmune responseImmune systemImmunizationImmunoglobulin Class SwitchingImmunoglobulin GImmunologic SurveillanceKnowledgeLibrariesMajor GrooveMass Spectrum AnalysisMeasurementMediatingMethodsModelingModificationMolecularMolecular StructureMusOligosaccharidesPathogenicityPathway interactionsPeptidesPlayPolysaccharidesPopulationProcessProductionPropertyProteinsRoleStreptococcus pneumoniaeStructureSurfaceSurface AntigensSystemT-Cell ReceptorT-LymphocyteT-Lymphocyte EpitopesTCR ActivationTimeVaccine DesignVaccine ResearchVaccinesadaptive immune responsebaseclinical practicecostdepolymerizationdesignexperimental studyhigh risk populationimmune activationimmune system functionimmunogenicinsightknowledge basemimeticsnovelolder patientpathogenic bacteriapeptide Iresponseuptakevaccine candidate
中文摘要
项目概要/摘要
大多数病原菌表达称为荚膜多糖(CPS)的表面碳水化合物。CPS是
重要的候选疫苗,因为它们位于细菌的最外表面,
不同的结构。这两个特征使它们很容易被免疫系统访问和识别。
监视,因此导致由B细胞产生CPS特异性抗体。诱导一种CPS特异性的
适应性免疫应答(即,T细胞介导的B细胞应答),CPS与载体蛋白缀合,
结合产物称为糖结合疫苗。由于对自己的认识不足,
免疫激活机制,目前的糖缀合物疫苗策略已经达到饱和,
很大程度上是对过去经验共轭方法的修改。当前一代的生产
糖缀合物疫苗是基于试验和错误,不利用特定的科学知识,
使关键免疫细胞的刺激最大化(即,辅助性T细胞)参与产生保护性IgG
抗体的一个新的视角,以碳水化合物为基础的疫苗研究是非常必要的。发生可能
建立一个新的范例,我们以前的发现和初步数据表明,哺乳动物
CD 4 + T细胞库包含碳水化合物特异性T细胞群(即,Tcarbs),
碳水化合物表位。在这里,我们建议扩大我们以前的发现,并定义分子
通过来自模型糖缀合物疫苗的碳水化合物表位激活Tcarb的机制。目标1,
本建议我们将通过主要组织相容性阐明碳水化合物呈递的结构要求
抗原呈递细胞(APC)表面上的II类复合物(MHCII)蛋白或纯化的MHCII
蛋白质相互作用研究。在目标2中,我们将在结构和功能上表征T细胞受体(TCR)
Tcarbs对聚糖表位的识别。我们相信,我们提出的研究将创造一个新的平台,
开发基于知识的糖缀合物疫苗,其富含功能性Tcarb表位。使用
发现Tcarb激活机制和聚糖表位的结构,我们可以设计和开发
新一代糖缀合物疫苗,将引起强烈和持久的免疫应答,
细菌感染。
英文摘要
Project Summary/Abstract
Most pathogenic bacteria express surface carbohydrates called capsular polysaccharides (CPSs). CPSs are
important vaccine candidates given that they are located on the outermost surface of bacteria and they have
distinct structures. These two features make them easily accessible and distinctly recognizable by immune
surveillance, therefore resulting in production of CPS specific antibodies by B cells. To induce a CPS specific
adaptive immune response (i.e., T cell-mediated B cell response), CPSs are conjugated with carrier proteins,
and the conjugation products are called glycoconjugate vaccines. Due to insufficient understanding of their
immune activation mechanisms, current glycoconjugate vaccine strategies have reached saturation and are
largely modifications of past empirical conjugation methods. The production of the current generation of
glycoconjugate vaccines is based on trial and error and does not make use of specific scientific knowledge to
maximize stimulation of critical immune cells (i.e., helper T cells) involved in producing protective IgG
antibodies. A new perspective to carbohydrate-based vaccine research is much needed. With the potential of
establishing a new paradigm, our previous discovery and preliminary data demonstrate that the mammalian
CD4+ T cell repertoire contains a population of carbohydrate-specific T cells (i.e., Tcarbs) that recognize
carbohydrate epitopes. Here, we propose to expand on our previous discovery and define the molecular
mechanisms for Tcarb activation by carbohydrate epitopes from a model glycoconjugate vaccine. In Aim 1 of
this proposal we will elucidate structural requirements for carbohydrate presentation by major histocompatibility
complex class II (MHCII) proteins on the surface of antigen presenting cells (APCs) or as purified MHCII
proteins via interaction studies. In Aim 2 we will structurally and functionally characterize T cell receptor (TCR)
recognition of glycan epitopes by Tcarbs. We believe our proposed studies will create a new platform to
develop knowledge-based glycoconjugate vaccines that are enriched for functional Tcarb epitopes. Using the
discovery of Tcarb activation mechanisms and of structures of glycan epitopes, we can design and develop
new-generation glycoconjugate vaccines that will elicit strong and long lasting immune response to protect
from bacterial infections.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Pn3Pase as an Effective Enzyme Therapeutic for Streptococcus Pneumoniae type 3 Infection
-
批准号:10324274
-
项目类别:
-
资助金额:$29.95万
-
财政年份:2021
-
负责人:Fikri Y Avci
-
依托单位:
Glycopeptide-specific helper T cells eliciting protective humoral immunity against HIV - Resubmission
-
批准号:10254963
-
项目类别:
-
资助金额:$52.85万
-
财政年份:2021
-
负责人:Fikri Y Avci
-
依托单位:
Glycopeptide-specific helper T cells eliciting protective humoral immunity against HIV - Resubmission
-
批准号:10368158
-
项目类别:
-
资助金额:$51.94万
-
财政年份:2021
-
负责人:Fikri Y Avci
-
依托单位:
Pn3Pase as an Effective Enzyme Therapeutic for Streptococcus Pneumoniae type 3 Infection
-
批准号:10448437
-
项目类别:
-
资助金额:$29.95万
-
财政年份:2021
-
负责人:Fikri Y Avci
-
依托单位:
Glycopeptide-specific helper T cells eliciting protective humoral immunity against HIV - Resubmission
-
批准号:10756630
-
项目类别:
-
资助金额:$52.85万
-
财政年份:2021
-
负责人:Fikri Y Avci
-
依托单位:
Molecular Mechanisms for Carbohydrate Presentation to CD4+ T cells by MHCII Pathway
-
批准号:10587072
-
项目类别:
-
资助金额:$46.51万
-
财政年份:2016
-
负责人:Fikri Y Avci
-
依托单位:
Molecular Mechanisms for Carbohydrate Presentation to CD4+ T cells by MHCII Pathway
-
批准号:10707369
-
项目类别:
-
资助金额:$46.51万
-
财政年份:2016
-
负责人:Fikri Y Avci
-
依托单位:
Molecular Mechanisms for Carbohydrate Presentation to CD4+ T cells by MHCII Pathway
-
批准号:9285694
-
项目类别:
-
资助金额:$37.5万
-
财政年份:2016
-
负责人:Fikri Y Avci
-
依托单位:
海外基金